久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

World-first drug to be launched in China

By Liu Zhihua | chinadaily.com.cn | Updated: 2018-12-19 13:36
Share
Share - WeChat
A worker leaves the AstraZeneca research facility in Loughborough, the United Kingdom. [Photo/Agencies]

AstraZeneca China announced on Tuesday that new anemia drug roxadustat has received approval from the National Medical Products Administration.

The drug was developed in collaboration with FibroGen China.

China has become the first country worldwide to approve the oral anemia treatment hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI).

AstraZeneca said the drug was expected to be launched in China during the second half of 2019.

Roxadustat, Chinese brand name Ai Rui Zhuo(愛瑞卓), has achieved three primary breakthroughs: it's the first drug to the adopt the HIF mechanism; the first of its kind developed and incubated in China, and the first approved in China before any other market globally, the company said.

FibroGen China was responsible for the clinical trials and registration of roxadustat in China, and now holds the certificate of drug registration issued by the NMPA.

Following the approval, FibroGen China will manage manufacturing, medical affairs and distribution.

AstraZeneca will manage its launch and commercialization.

According to the NMPA approval, roxadustat is to be used in the treatment of anemia caused by chronic kidney disease (CKD) in patients who are dialysis-dependent (DD).The medicine can be prescribed to patients who use hemodialysis or peritoneal dialysis.

There are over 120 million CKD patients in China, and anemia is one of the complications of CKD, occurring at a rate of up to 98.2 percent in patients on dialysis, according to medical journals Lancet and Chinese Journal of Nephrology.

If anemia is not controlled, it increases cardiovascular risks, as well as mortality in patients on dialysis, and may affect patients' mental health and social functions, imposing a heavy burden on patients, their families and society.

According to clinical data in China, roxadustat can effectively increase and keep hemoglobin in dialysis patients with anemia caused by CKD, AstraZeneca said.

The development of roxadustat ends a long period in which there were no new drugs developed by a new mechanism for the treatment of CKD-caused anemia, said Chen Xiangmei, member of the Chinese Academy of Engineering and head of the PLA Institute of Kidney Diseases.

AstraZeneca also attributed the fast approval to the Chinese government's efforts in supporting pharmaceutical innovation and providing more quality new drugs to Chinese patients.

Leon Wang, executive vice president, international and China President at AstraZeneca, said: "Roxadustat's approval in China demonstrated the determination of the Chinese government in accelerating the supply of urgently needed new drugs to Chinese patients and supporting pharmaceutical innovation.

"In the future, AstraZeneca will work closely with the government to increase the accessibility of roxadustat in China and benefit more Chinese patients.

"At the same time, in response to the Chinese government's call for pharmaceutical innovation, we will build the local incubation platform to make more novel drugs benefiting Chinese patients first and open up China's pharmaceutical innovations to the world."

Chen Nan, a professor with Shanghai Jiao Tong University School of Medicine, who led principal investigator in the phase-three clinical trial of roxadustat in China, said: "Thanks to the improvement of China's pharmaceutical innovation atmosphere, Chinese researchers now have much better chance to show their excellence together with international peers, to further the global clinical development of first-in-class innovative drugs and to succeed in incubating them in China first.

"Our work is taking the lead not only in terms of speed, but also meets international standards in terms of quality, which demonstrates the research and development strength of China's healthcare professionals."

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 免费观看成年人网站 | 日韩一级黄色 | 九九精彩视频在线观看视频 | 香港三级做爰大爽视频 | 1024手机基地在线看手机 | 久久精品国产屋 | mm在线精品视频 | 欧美一级视频在线 | 91小视频在线观看免费版高清 | 日本免费视频观看在线播放 | 日本无卡码免费一区二区三区 | 久草视频在线免费播放 | 中国一级毛片aaa片 中国一级毛片录像 | 小明日韩在线看看永久区域 | 美国亚洲成年毛片 | 99在线免费观看视频 | 中文精品久久久久国产网址 | 美女被免费视频网站a国产 美女被免费网站视频软件 美女被免费网站在线软件 美女被免费网站在线视频软件 | 国产免费爽爽视频免费可以看 | 三级毛片在线免费观看 | 九九色网 | 免费毛片播放 | 免费三级网址 | 成人a毛片在线看免费全部播放 | 亚洲午夜色 | 久久久久9999| 成人欧美日韩 | 九九re6精品视频在线观看 | 亚洲欧洲日本天天堂在线观看 | 日韩黄色一级毛片 | 国产成人免费午夜在线观看 | 自拍在线视频 | 一级毛毛片毛片毛片毛片在线看 | 国产精品欧美一区二区 | 久草资源在线播放 | 在线成人aa在线看片 | 亚洲第一视频在线播放 | 亚洲精品国产三级在线观看 | 毛片手机在线视频免费观看 | 搞黄网站免费看 | 国产精品尹人在线观看免费 |